Yahoo Finance

Invizius completes Phase I trial of dialysis priming product H-Guard

Scotland-based biotech Invizius has completed a Phase I clinical study, assessing its dialysis priming product H-Guard. H-Guard is a specialised medical device coating indicated for use in dialysis ...
PharmiWeb

Invizius’s Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study

Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis. Encouraging biomarker data ...
PharmaTimes

Invizius gets MHRA Approval for H-Guard research

First-in-human study to be undertaken at the Manchester University Hospitals NHS Foundation Trust First-in-human study to be undertaken at the Manchester University Hospitals NHS Foundation Trust ...
Finanznachrichten

Invizius Receives MHRA Approval to Commence First-in-Human Clinical Study of H-Guard Priming Solution

H-Guard® will be evaluated for its safety and efficacy to address serious complement driven complications of haemodialysis GLASGOW, Scotland, Aug. 1, 2023 /PRNewswire/ -- Invizius Limited ("Invizius") ...